Skip to main content

Table 5 Utilities associated with the health states of the model [Source: [17]]

From: Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

Health state (N of letters)

Utilitya

86 to 100

0.92

71 to 85

0.82

56 to 70

0.72

41 to 55

0.63

26 to 40

0.53

0 to 25

0.40

  1. athe study Hodgson et al. 2017 [17] estimated the relationship between QoL and visual acuity using two regression models: one for the QoL associated with better seeing eye (BSE), one for the QoL associated with worse seeing eye (WSE). In the present analysis, only the second regression model was used, assuming that in clinical trials the drug treatment was always carried out on the eye with worse visual acuity
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us